Bristol-Myers Squibb (NYSE:BMY) Shares Sold by MTM Investment Management LLC

MTM Investment Management LLC trimmed its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,236 shares of the biopharmaceutical company’s stock after selling 1,023 shares during the period. MTM Investment Management LLC’s holdings in Bristol-Myers Squibb were worth $1,371,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of BMY. AMF Tjanstepension AB grew its holdings in Bristol-Myers Squibb by 6.9% in the third quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock valued at $31,618,000 after purchasing an additional 39,419 shares during the period. Exchange Traded Concepts LLC boosted its stake in shares of Bristol-Myers Squibb by 18.1% in the third quarter. Exchange Traded Concepts LLC now owns 26,468 shares of the biopharmaceutical company’s stock worth $1,369,000 after acquiring an additional 4,064 shares during the last quarter. Procyon Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 3.4% in the third quarter. Procyon Advisors LLC now owns 17,237 shares of the biopharmaceutical company’s stock worth $891,000 after acquiring an additional 572 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in shares of Bristol-Myers Squibb in the third quarter worth approximately $34,000. Finally, Occidental Asset Management LLC boosted its stake in shares of Bristol-Myers Squibb by 9.7% in the third quarter. Occidental Asset Management LLC now owns 10,021 shares of the biopharmaceutical company’s stock worth $518,000 after acquiring an additional 886 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

BMY opened at $56.17 on Thursday. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.10. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The business’s 50-day simple moving average is $57.42 and its 200-day simple moving average is $54.00.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.81% and a negative net margin of 18.53%. As a group, analysts forecast that Bristol-Myers Squibb will post 6.75 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 4.42%. The ex-dividend date was Friday, January 3rd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -56.11%.

Analysts Set New Price Targets

A number of research firms have commented on BMY. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Bank of America restated a “neutral” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Cantor Fitzgerald lifted their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Sanford C. Bernstein began coverage on Bristol-Myers Squibb in a research report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 target price on the stock. Finally, Truist Financial increased their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $57.86.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.